Developing a new treatment for dry eye disease caused by Sjogren's syndrome
Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease
['FUNDING_SBIR_2'] · STELLULAR BIO, INC. · NIH-11067525
This study is testing a new, easy-to-get treatment for dry eyes caused by Sjogren's syndrome, using special cells to create a healing extract that could help improve your symptoms and overall eye health.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STELLULAR BIO, INC. (nih funded) |
| Locations | 1 site (WATERTOWN, UNITED STATES) |
| Trial ID | NIH-11067525 on ClinicalTrials.gov |
What this research studies
This research focuses on creating an innovative off-the-shelf therapy for Sjogren's syndrome-related dry eye disease, which affects millions of people. The approach involves using induced pluripotent stem cells to produce a unique extract that contains growth factors and cytokines aimed at promoting healing in the cornea and alleviating symptoms. By providing a fast-acting and disease-modifying treatment, this research aims to improve the quality of life for patients suffering from this condition. The therapy is designed to be readily available and does not require individualized manufacturing, making it more accessible to patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Sjogren's syndrome who experience dry eye symptoms.
Not a fit: Patients with dry eye disease not related to Sjogren's syndrome may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option that significantly alleviates symptoms and improves the quality of life for patients with Sjogren's syndrome-related dry eye disease.
How similar studies have performed: Previous research has shown promise with similar approaches using autologous blood products, indicating potential for success with this novel off-the-shelf therapy.
Where this research is happening
WATERTOWN, UNITED STATES
- STELLULAR BIO, INC. — WATERTOWN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DYKSTRA, BRADFORD — STELLULAR BIO, INC.
- Study coordinator: DYKSTRA, BRADFORD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, autoimmune disorder, autoimmunity disease